Last updated: March 10, 2023
Sponsor: Beijing Tiantan Hospital
Overall Status: Completed
Phase
N/A
Condition
Stroke
Hemorrhage
Adverse Effects, Drugs
Treatment
N/AClinical Study ID
NCT05766865
KY2019-096-02
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- (1) 18-75 years old;
- (2) non-traumatic intracerebral hemorrhage;
- (3) severe intracerebral hemorrhage, which was defined as patients with supratentorialbleeding volume > 30 ml, infratentorial bleeding volume > 10 ml, midline shift > 1 cm,or large intraventricular hematoma;
- (4) Glasgow coma score (GCS) < 13;
- (5) family members agree to provide an informed written consent.
Exclusion
Exclusion Criteria:
- (1) patients had cerebrovascular diseases, e.g., intracranial aneurysm or vascularmalformation, and intracranial tumors, which were associated with hemorrhage;
- (2) hemorrhagic transformation of cerebral infarction;
- (3) hemorrhage caused by venous thrombosis;
- (4) patients with severe coagulation disorder, e.g., hemophilia;
- (5) patients with coagulation dysfunction caused by malignant tumor, hepaticinsufficiency, renal dysfunction, thrombocytopenia, coagulation diseases, and so on;
- (6) patients receiving other anticoagulation medications (vitamin K antagonist and neworal anticoagulants);
- (7) patients not on LOAPT who receive conservative treatment;
- (8) the patients who died before or on arriving at the hospital and within a shortperiod (6 h) after admission.
Study Design
Total Participants: 450
Study Start date:
July 10, 2019
Estimated Completion Date:
November 30, 2022
Connect with a study center
Capital Medical University Affiliated Beijing Tiantan Hospital
Beijing, Beijing
ChinaSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.